
TY  - JOUR
TI  - POSTER SESSIONS
JO  - Allergy
VL  - 62
IS  - s83
SN  - 0105-4538
UR  - https://doi.org/10.1111/j.1398-9995.2007.01407.x
DO  - doi:10.1111/j.1398-9995.2007.01407.x
SP  - 167
EP  - 551
PY  - 2007
ER  - 

TY  - JOUR
TI  - Acute coronary syndromes, myocardial infarction, thrombectomy and vulnerable plaque
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 85
IS  - S2
SN  - 1522-1946
UR  - https://doi.org/10.1002/ccd.25910
DO  - doi:10.1002/ccd.25910
SP  - S1
EP  - S176
PY  - 2015
ER  - 

TY  - JOUR
TI  - Posters (Abstracts 72 to 394)
JO  - Clinical Oral Implants Research
VL  - 19
IS  - 9
SN  - 0905-7161
UR  - https://doi.org/10.1111/j.1600-0501.2008.01625_2.x
DO  - doi:10.1111/j.1600-0501.2008.01625_2.x
SP  - 860
EP  - 967
PY  - 2008
ER  - 

TY  - JOUR
TI  - ACR Meeting
JO  - Arthritis & Rheumatism
JA  - Arthritis & Rheumatism
VL  - 64
IS  - S10
SN  - 0004-3591
UR  - https://doi.org/10.1002/art.37735
DO  - doi:10.1002/art.37735
SP  - S1
EP  - S1216
PY  - 2012
AB  - Abstract http://acrmeeting.wiley.com/
ER  - 

TY  - JOUR
TI  - Abstracts from the 10th World Congress for Microcirculation
JO  - Microcirculation
JA  - Microcirculation
VL  - 22
IS  - 7
SN  - 1073-9688
UR  - https://doi.org/10.1111/micc.12246
DO  - doi:10.1111/micc.12246
SP  - 542
EP  - 676
PY  - 2015
ER  - 

TY  - JOUR
TI  - ANNUAL MEETING NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY CHARLESTON, SOUTH CAROLINA NOVEMBER 14–18, 1999
JO  - Obesity Research
VL  - 7
IS  - s1
SN  - 1071-7323
UR  - https://doi.org/10.1002/j.1550-8528.1999.tb00444.x
DO  - doi:10.1002/j.1550-8528.1999.tb00444.x
SP  - 1S
EP  - 131S
PY  - 1999
ER  - 

TY  - JOUR
AU  - Malchesky, Paul S.
TI  - Artificial Organs 2013: A Year in Review
JO  - Artificial Organs
JA  - Artificial Organs
VL  - 38
IS  - 3
SN  - 0160-564X
UR  - https://doi.org/10.1111/aor.12284
DO  - doi:10.1111/aor.12284
SP  - 239
EP  - 267
KW  - Apheresis
KW  - Biocompatibility
KW  - Bioengineering
KW  - Biomaterials
KW  - Blood substitutes
KW  - Blood pumps
KW  - Cardiac support
KW  - Cardiopulmonary
KW  - Dermal
KW  - Dialysis
KW  - Liver
KW  - Lung
KW  - Membrane oxygenation
KW  - Organ preservaion
KW  - Orthopedic
KW  - Neuromuscular
KW  - Pancreas
KW  - Pulmonary
KW  - Renal
KW  - Surgery
KW  - Tissue engineering
KW  - Transplantation
KW  - Valves
KW  - Vascular
KW  - Vision
PY  - 2014
AB  - Abstract In this Editor's Review, articles published in 2013 are organized by category and briefly summarized. We aim to provide a brief reflection of the currently available worldwide knowledge that is intended to advance and better human life while providing insight for continued application of technologies and methods of organ Replacement, Recovery, and Regeneration. As the official journal of The International Federation for Artificial Organs, The International Faculty for Artificial Organs, the International Society for Rotary Blood Pumps, the International Society for Pediatric Mechanical Cardiopulmonary Support, and the Vienna International Workshop on Functional Electrical Stimulation, Artificial Organs continues in the original mission of its founders ?to foster communications in the field of artificial organs on an international level?. Artificial Organs continues to publish developments and clinical applications of artificial organ technologies in this broad and expanding field of organ Replacement, Recovery, and Regeneration from all over the world. We take this time also to express our gratitude to our authors for offering their work to this journal. We offer our very special thanks to our reviewers who give so generously of time and expertise to review, critique, and especially provide so meaningful suggestions to the author's work whether eventually accepted or rejected and especially to those whose native tongue is not English. Without these excellent and dedicated reviewers the quality expected from such a journal could not be possible. We also express our special thanks to our Publisher, Wiley Periodicals, for their expert attention and support in the production and marketing of Artificial Organs. We look forward to recording further advances in the coming years.
ER  - 

TY  - JOUR
TI  - Posters
JO  - European Journal of Clinical Investigation
JA  - Eur J Clin Invest
VL  - 49
IS  - S1
SN  - 0014-2972
UR  - https://doi.org/10.1111/eci.13109
DO  - doi:10.1111/eci.13109
SP  - 101
EP  - 221
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster session abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 18
IS  - S10
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.1950180707
DO  - doi:10.1002/ppul.1950180707
SP  - 179
EP  - 305
PY  - 1994
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 22
IS  - 3
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.410220329
DO  - doi:10.1002/ana.410220329
SP  - 406
EP  - 454
PY  - 1987
ER  - 

TY  - JOUR
TI  - Abstracts of The Annual Meeting
JO  - Hepatology
JA  - Hepatology
VL  - 5
IS  - 5
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.1840050545
DO  - doi:10.1002/hep.1840050545
SP  - 947
EP  - 1063
PY  - 1985
ER  - 

TY  - JOUR
TI  - European Society for Veterinary Clinical Pathology (ESVCP) 13th Annual Congress
JO  - Veterinary Clinical Pathology
JA  - Vet Clin Pathol
VL  - 41
IS  - 1
SN  - 0275-6382
UR  - https://doi.org/10.1111/j.1939-165X.2011.00375.x
DO  - doi:10.1111/j.1939-165X.2011.00375.x
SP  - E1
EP  - E16
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts of the annual meeting
JO  - Hepatology
JA  - Hepatology
VL  - 6
IS  - 5
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.1840060557
DO  - doi:10.1002/hep.1840060557
SP  - 1105
EP  - 1231
PY  - 1986
ER  - 

TY  - JOUR
AU  - Fevery, Johan
TI  - Bilirubin in clinical practice: a review
JO  - Liver International
VL  - 28
IS  - 5
SN  - 1478-3223
UR  - https://doi.org/10.1111/j.1478-3231.2008.01716.x
DO  - doi:10.1111/j.1478-3231.2008.01716.x
SP  - 592
EP  - 605
KW  - bilirubin
KW  - cholestasis
KW  - Gilbert's syndrome
KW  - glucuronyltransferase
KW  - haemolysis
PY  - 2008
AB  - Abstract Bilirubin is an endogenous compound that can be toxic under certain conditions but, on the other hand, mild unconjugated hyperbilirubinaemia might protect against cardiovascular diseases and tumour development. Serum bilirubin levels are often enhanced under a variety of clinical conditions. These are discussed and the mechanisms are outlined.
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr. Pulmonol.
VL  - 47
IS  - S35
SN  - 8755-6863
UR  - https://doi.org/10.1002/ppul.22682
DO  - doi:10.1002/ppul.22682
SP  - 223
EP  - 446
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Hepatology
JA  - Hepatology
VL  - 54
IS  - S1
SN  - 0270-9139
UR  - https://doi.org/10.1002/hep.24666
DO  - doi:10.1002/hep.24666
SP  - 360A
EP  - 1455A
PY  - 2011
ER  - 

TY  - JOUR
TI  - Moderated Posters
JO  - Transplant International
JA  - Transpl Int
VL  - 30
IS  - S2
SN  - 0934-0874
UR  - https://doi.org/10.1111/tri.13052
DO  - doi:10.1111/tri.13052
SP  - 370
EP  - 389
PY  - 2017
ER  - 

TY  - JOUR
AU  - Brinkmalm, Ann
AU  - Portelius, Erik
AU  - Brinkmalm, Gunnar
AU  - Pannee, Josef
AU  - Dahlén, Rahil
AU  - Gobom, Johan
AU  - Blennow, Kaj
AU  - Zetterberg, Henrik
TI  - Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases
JO  - Journal of Neurochemistry
JA  - J. Neurochem.
VL  - 151
IS  - 4
SN  - 0022-3042
UR  - https://doi.org/10.1111/jnc.14594
DO  - doi:10.1111/jnc.14594
SP  - 417
EP  - 434
KW  - biomarkers
KW  - CSF
KW  - Neurodegeneration
KW  - plasma
KW  - proteomics
KW  - serum
PY  - 2019
AB  - Abstract Neurodegenerative dementias constitute a broad group of diseases in which abnormally folded proteins accumulate in specific brain regions and result in tissue reactions that eventually cause neuronal dysfunction and degeneration. Depending on where in the brain this happens, symptoms appear which may be used to classify the disorders on clinical grounds. However, brain changes in neurodegenerative dementias start to accumulate many years prior to symptom onset and there is a poor correlation between the clinical picture and what pathology that is the most likely to cause it. Thus, novel drug candidates having disease-modifying effects that is targeting the underlying pathology and changes the course of the disease needs to be defined using objective biomarker-based measures since the clinical symptoms are often non-specific and overlap between different disorders. Furthermore, the treatment should ideally be initiated as soon as symptoms are evident or when biomarkers confirm an underlying pathology (pre-clinical phase of the disease) to reduce irreversible damage to, for example, neurons, synapses and axons. Clinical trials in the pre-clinical phase bring a greater importance to biomarkers since by definition the clinical effects are difficult or slow to discern in a population that is not yet clinically affected. Here, we discuss neuropathological changes that may underlie neurodegenerative dementias, including how they can be detected and quantified using currently available biofluid-based biomarkers and how more of them could be identified using targeted proteomics approaches. This article is part of the special issue 'Proteomics'.
ER  - 

TY  - JOUR
AU  - Herold, Kristina
AU  - Mrowka, Ralf
C7  - e13284
TI  - Inflammation—Dysregulated inflammatory response and strategies for treatment
JO  - Acta Physiologica
JA  - Acta Physiol
VL  - 226
IS  - 3
SN  - 1748-1708
UR  - https://doi.org/10.1111/apha.13284
DO  - doi:10.1111/apha.13284
SP  - e13284
PY  - 2019
ER  - 

C7  - pp. 3441-3551
TI  - Index
SN  - 9781405169110
UR  - https://doi.org/10.1002/9781444303254.index
DO  - doi:10.1002/9781444303254.index
SP  - 3441-3551
PY  - 2019
ER  - 
